Cargando…

The changing treatment landscape in idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible fibrotic disease of the lung that has greatly frustrated clinicians for a long time. The prognosis of IPF (median survival 2–5 years following diagnosis) is poorer than that of some cancers and for many years no significa...

Descripción completa

Detalles Bibliográficos
Autor principal: Costabel, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487773/
https://www.ncbi.nlm.nih.gov/pubmed/25726557
http://dx.doi.org/10.1183/09059180.00011414
_version_ 1784792517249597440
author Costabel, Ulrich
author_facet Costabel, Ulrich
author_sort Costabel, Ulrich
collection PubMed
description Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible fibrotic disease of the lung that has greatly frustrated clinicians for a long time. The prognosis of IPF (median survival 2–5 years following diagnosis) is poorer than that of some cancers and for many years no significant advances were made in its management. However, between 2011 and 2014 a number of pivotal developments were made that have improved the outlook for patients with IPF. Herein, we review this rapidly changing landscape, discussing key events whilst still acknowledging that IPF remains a challenging disease to diagnose and manage.
format Online
Article
Text
id pubmed-9487773
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-94877732022-11-14 The changing treatment landscape in idiopathic pulmonary fibrosis Costabel, Ulrich Eur Respir Rev Reviews Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible fibrotic disease of the lung that has greatly frustrated clinicians for a long time. The prognosis of IPF (median survival 2–5 years following diagnosis) is poorer than that of some cancers and for many years no significant advances were made in its management. However, between 2011 and 2014 a number of pivotal developments were made that have improved the outlook for patients with IPF. Herein, we review this rapidly changing landscape, discussing key events whilst still acknowledging that IPF remains a challenging disease to diagnose and manage. European Respiratory Society 2015-03 /pmc/articles/PMC9487773/ /pubmed/25726557 http://dx.doi.org/10.1183/09059180.00011414 Text en Copyright ©ERS 2015. https://creativecommons.org/licenses/by-nc/4.0/ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Reviews
Costabel, Ulrich
The changing treatment landscape in idiopathic pulmonary fibrosis
title The changing treatment landscape in idiopathic pulmonary fibrosis
title_full The changing treatment landscape in idiopathic pulmonary fibrosis
title_fullStr The changing treatment landscape in idiopathic pulmonary fibrosis
title_full_unstemmed The changing treatment landscape in idiopathic pulmonary fibrosis
title_short The changing treatment landscape in idiopathic pulmonary fibrosis
title_sort changing treatment landscape in idiopathic pulmonary fibrosis
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487773/
https://www.ncbi.nlm.nih.gov/pubmed/25726557
http://dx.doi.org/10.1183/09059180.00011414
work_keys_str_mv AT costabelulrich thechangingtreatmentlandscapeinidiopathicpulmonaryfibrosis
AT costabelulrich changingtreatmentlandscapeinidiopathicpulmonaryfibrosis